ArticlePatient preference and adherence2018
Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
Article in Patient preference and adherence, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Health utility values associated with pharmaceutical treatment process attributes: a systematic review and meta-analysis.Health and quality of life outcomes · 2026Pooled it
- Pooled it
- Disutilities of treatment-related attributes for type 2 diabetes mellitus: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Pooled it
- Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).Diabetes, obesity & metabolism · 2020 · on this mapTrial
- Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.Diabetes, obesity & metabolism · 2026Article
- Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study.PharmacoEconomics - open · 2026Article
- Utilities Associated with the Treatment of Growth Hormone Deficiency (GHD): A Time Trade-off (TTO) Study in the UK and Canada.Patient related outcome measures · 2025Article
- Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.Advances in therapy · 2022Article
- Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes.Patient related outcome measures · 2022Review
- Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021Article
- Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021Article
- Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.Patient preference and adherence · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSeveral glucagon-like peptide-1 receptor agonists are administered as weekly injections for treatment of type 2 diabetes (T2D). These medications vary in their injection processes, and a recent study in the UK found that these differences had an impact on patient preference and health state utilities. The purpose of this study was to replicate the UK study in Italy to examine preferences of an Italian patient sample, while allowing for comparison between utilities in the UK and Italy. MATERIALS AND
methodsParticipants with T2D in Italy valued health states in time trade-off interviews. All health states had the same description of T2D, but differed in description of the treatment process. As in the original UK study, the first health state described an oral treatment regimen, while additional health states added a weekly injection. The injection health states differed in three injection-related attributes: requirements for reconstituting the medication, waiting during medication preparation, and needle handling.
resultsInterviews were completed by 238 patients (58.8% male; mean age = 60.2 years; 118 from Milan, 120 from Rome). The oral treatment health state had a mean (SD) utility of 0.90 (0.10). The injection health states had significantly (
conclusionDisutilities associated with the injection device characteristics were similar to those reported with the UK sample. Results suggest that injection device attributes may be important to some patients with T2D, and it may be useful for clinicians to consider these attributes when choosing medication for patients initiating these weekly treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.